Association between tamoxifen treatment and diabetes: A population-based study

Cancer

Volumn 118, Issue 10, 2012, Pages 2615-2622

  Lipscombe, Lorraine L ^a,b,c,d   Fischer, Hadas D ^c   Yun, Lingsong ^c   Gruneir, Andrea ^a,d   Austin, Peter ^c,d   Paszat, Lawrence ^c,d,e   Anderson, Geoff M ^c,d   Rochon, Paula A ^a,b,c,d  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

adjuvant hormonal therapy; breast cancer; diabetes; estrogen deficiency; tamoxifen

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN; GLUCOCORTICOID; PROGESTERONE; RALOXIFENE; TAMOXIFEN;

AGED; ARTICLE; BREAST CANCER; CANADA; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVOR; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG EXPOSURE; DRUG USE; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DIABETES MELLITUS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 84860652546     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26559     Document Type: Article

References (32)

1. Larsson SC, Mantzoros CS, Wolk A,. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007; 121: 856-862.
2. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE,. Diabetes mellitus and breast cancer: a retrospective population-based cohort study. Breast Cancer Res Treat. 2006; 98: 349-356.
3. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE,. The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat. 2008; 109: 389-395.
4. Peairs KS, Barone BB, Snyder CF, et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol. 2011; 29: 40-46.
5. Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008; 300: 2754-2764.
6. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE,. Increased prevalence of prior breast cancer in women with newly diagnosed diabetes. Breast Cancer Res Treat. 2006; 98: 303-309.
7. Bordeleau L, Lipscombe L, Lubinski J, et al. Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. Cancer. 2011; 117: 1812-1818.
8. Canadian Cancer Society, National Cancer Institute of Canada. Canadian Cancer Statistics 2006. Available at: Accessed on April 22, 2011.
9. McCarthy NJ,. Care of the breast cancer survivor: increased survival rates present a new set of challenges. Postgrad Med. 2004; 116: 39-40, 42, 45-46.
10. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ,. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005; 16: 1569-1583.
11. Liu S, Mauvais-Jarvis F,. Rapid, nongenomic estrogen actions protect pancreatic islet survival. Islets. 2009; 1: 273-275.
12. Liu S, Mauvais-Jarvis F,. Minireview: Estrogenic protection of beta-cell failure in metabolic diseases. Endocrinology. 2010; 151: 859-864.
13. Louet JF, LeMay C, Mauvais-Jarvis F,. Antidiabetic actions of estrogen: insight from human and genetic mouse models. Curr Atheroscler Rep. 2004; 6: 180-185.
14. Barros RP, Machado UF, Gustafsson JA,. Estrogen receptors: new players in diabetes mellitus. Trends Mol Med. 2006; 12: 425-431.
15. Godsland IF,. Oestrogens and insulin secretion. Diabetologia. 2005; 48: 2213-2220.
16. Bryzgalova G, Gao H, Ahren B, et al. Evidence that oestrogen receptor-alpha plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver. Diabetologia. 2006; 49: 588-597.
17. Le May C, Chu K, Hu M, et al. Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci U S A. 2006; 103: 9232-9237.
18. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/Progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003; 138: 1-9.
19. Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia. 2004; 47: 1175-1187.
20. Garreau JR, Delamelena T, Walts D, Karamlou K, Johnson N,. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective. Am J Surg. 2006; 192: 496-498.
21. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D,. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003; 10: 67-71.
22. Robles SC, Marrett LD, Clarke EA, Risch HA,. An application of capture-recapture methods to the estimation of completeness of cancer registration. J Clin Epidemiol. 1988; 41: 495-501.
23. Hux JE, Ivis F, Flintoft V, Bica A,. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002; 25: 512-516.
24. Deyo RA, Cherkin DC, Ciol MA,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613-619.
25. Wild S, Roglic G, Green A, Sicree R, King H,. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27: 1047-1053.
26. Carr MC,. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003; 88: 2404-2411.
27. Elisaf MS, Nakou K, Liamis G, Pavlidis NA,. Tamoxifen-induced severe hypertriglyceridemia and pancreatitis. Ann Oncol. 2000; 11: 1067-1069.
28. Nguyen MC, Stewart RB, Banerji MA, Gordon DH, Kral JG,. Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer. Int J Obes Relat Metab Disord. 2001; 25: 296-298.
29. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011; 103: 250-263.
30. Suzuki R, Orsini N, Saji S, Key TJ, Wolk A,. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status-a meta-analysis. Int J Cancer. 2009; 124: 698-712.
31. Wolf I, Sadetzki S, Gluck I, et al. Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. Eur J Cancer. 2006; 42: 1077-1082.
32. Maiti B, Kundranda MN, Spiro TP, Daw HA,. The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Res Treat. 2010; 121: 479-483.